Nogapendekin alfa inbakicept-pmln in Urothelial Carcinoma of the Urinary Bladder: NCT07217496 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
not reported
Planned enrollment
2028-01-01
Primary-completion proxy
Executive view
NCT07217496 evaluates Nogapendekin alfa inbakicept-pmln in Urothelial Carcinoma of the Urinary Bladder. The disclosed sponsor is ImmunityBio, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Assess the safety and tolerability of the treatment regimen (NAI, EV, and pembrolizumab)., assessed over From the date of first dose of study product to 30 days after the last dose of study product..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07217496 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Urothelial Carcinoma of the Urinary Bladder landscape. Drug & Asset MCP drug_fetch was queried for Nogapendekin alfa inbakicept-pmln, while Company & Deal Intelligence MCP organization_fetch was queried for ImmunityBio, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07217496 | Nogapendekin alfa inbakicept-pmln | Phase 1 / Not yet recruiting | ImmunityBio, Inc. | United States | Assess the safety and tolerability of the treatment regimen (NAI, EV, and pembrolizumab). From the date of first dose of study product to 30 days after the las… | 2028-01-01 |
| NCT07222488 | SKB410 | Phase 1/2 / Recruiting | Merck Sharp & Dohme LLC | Greece, Canada, Netherlands, Austria, Belgium, Norway, United States, Turkey, Italy, Israel, France, Spain | Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Up to approximately 5 weeks | 2029-02-28 |
| NCT07218380 | Vepugratinib | Phase 3 / Recruiting | Eli Lilly & Co. | Hungary, Czechia, United States, Japan, United Kingdom, Spain, Canada, South Korea, Netherlands, China, Turkey, Taiwan Province, Poland, Denmark, Brazil, Italy, France, Australia, Germany | Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrol… From baseline up to 90 months | 2029-10-01 |
| NCT07217171 | EVOLVE-104 | Phase 1 / Recruiting | EvolveImmune United, Inc | United States | Incidence and Severity of Treatment Emergent Adverse Events (TEAEs) Baseline, through study completion, an average of 10 months. | 2029-01-29 |
| NCT07207824 | Disitamab Vedotin | Phase 3 / Recruiting | Fudan University | China | Event free survival 55 months after first participant randomized | 2030-06-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07217496 is a Phase 1, not yet recruiting study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Assess the safety and tolerability of the treatment regimen (NAI, EV, and pembrolizumab).” over “From the date of first dose of study product to 30 days after the last dose of study product..” The retrieved endpoint description is: The proportion of participants with treatment-emergent adverse events (TEAEs), as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.0..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Urothelial Carcinoma of the Urinary Bladder. These records do not establish direct evidence for NCT07217496 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Nogapendekin alfa inbakicept-pmln is indexed as Fc fusion protein with IL-2Rβγ biology and a global stage of Approved. The asset profile lists Altor BioScience Corp. as an originator or developer.
ImmunityBio, Inc. is indexed in an unreported country with the website http://www.immunitybio.com. ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer. The record lists 17 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Nogapendekin alfa inbakicept-pmln is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07217496
Protocol source: https://clinicaltrials.gov/study/NCT07217496
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
Nogapendekin alfa inbakicept-pmln in Urothelial Carcinoma of the Urinary Bladder is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Assess the safety and tolerability of the treatment regimen (NAI, EV, and pembrolizumab). and 2028-01-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
